Pfizer’s First Ibrance Phase III Stopped Early For Efficacy
This article was originally published in The Pink Sheet Daily
Executive Summary
The Phase III trial PALOMA-3 enrolled patients with a similar type of breast cancer as those in the Phase II study that served as the basis of palbociclib’s accelerated approval earlier this year, but in a relapsed setting.